Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020

Rhea-AI Summary

Cara Therapeutics (Nasdaq: CARA) announced a conference call scheduled for November 9, 2020, at 4:30 p.m. ET to discuss its Q3 2020 financial results and provide a corporate update. The call can be accessed through domestic and international phone lines, and a live webcast will be available on the company’s website. Cara focuses on developing treatments for pruritus, particularly KORSUVA™, which has shown promising results in clinical trials targeting kidney disease-associated itching. The FDA has conditionally accepted KORSUVA as the trade name for its investigational drug.

Positive

• KORSUVA Injection showed statistically significant reductions in itch intensity in Phase 3 trials.
• Completed Phase 2 trial of Oral KORSUVA, expanding treatment options for CKD-associated pruritus.
• The FDA has conditionally accepted KORSUVA as the trade name for difelikefalin injection.

Negative

• None.

STAMFORD, Conn., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, November 9, 2020, at 4:30 p.m. ET to report third quarter 2020 financial results and provide a corporate update.

To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 2192536. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Cara has successfully completed its Phase 2 trial of Oral KORSUVA for the treatment of pruritus in patients with CKD and is currently conducting Phase 2 trials of Oral KORSUVA in atopic dermatitis and primary biliary cholangitis patients with moderate-to-severe pruritus.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

INVESTOR CONTACT:
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@SternIR.com

MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com

FAQ

When is Cara Therapeutics' Q3 2020 earnings call?

Cara Therapeutics will host its Q3 2020 earnings call on November 9, 2020, at 4:30 p.m. ET.

What is KORSUVA and its significance for Cara Therapeutics?

KORSUVA is an investigational drug designed to alleviate pruritus and has shown positive results in clinical trials for patients with chronic kidney disease.

How has KORSUVA performed in clinical trials?

KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and improved quality of life for hemodialysis patients.

Where can I access the Cara Therapeutics earnings call?

The earnings call can be accessed through a live audio webcast on Cara Therapeutics' website.